A randomized, double‐blind, placebo‐controlled trial to evaluate the efficacy, safety, and tolerability of long‐term treatment with prucalopride

Randomized trials have confirmed the efficacy of prucalopride for the treatment of chronic constipation up to 12 weeks. This study aimed to assess the efficacy of prucalopride over a 24‐week period (ClinicalTrials.gov: NCT01424228).

• Publication year

  2015

• Venue

  Neurogastroenterology and Motility

• Publication date

  2015-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/nmo.12553PMID 25808103
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• World Medical Association Declaration of Helsinki (WMA) - Ethical principles for medical research involving human subjects

  2014cited by this paper
• Levels of satisfaction with current chronic constipation treatment options in Europe – an internet survey

  2013cited by this paper
• Efficacy and safety of oral prucalopride in women with chronic constipation in whom laxatives have failed: an integrated analysis

  2013cited by this paper
• Factors associated with persistent and nonpersistent chronic constipation, over 20 years.

  2012cited by this paper
• Prucalopride in the treatment of chronic constipation in patients from the Asia-Pacific region: a randomized, double-blind, placebo-controlled study

  2012cited by this paper
• Psychometric performance and clinical meaningfulness of the Patient Assessment of Constipation – Quality of Life questionnaire in prucalopride (RESOLOR®) trials for chronic constipation

  2010cited by this paper
• A double‐blind, placebo‐controlled study of prucalopride in elderly patients with chronic constipation

  2010cited by this paper
• Clinical trial: the efficacy of open‐label prucalopride treatment in patients with chronic constipation – follow‐up of patients from the pivotal studies

  2010cited by this paper
• Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation – a 12‐week, randomized, double‐blind, placebo‐controlled study

  2009cited by this paper
• A placebo-controlled trial of prucalopride for severe chronic constipation.

  2008cited by this paper
• Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives

  2008cited by this paper
• Chronic constipation: a survey of the patient perspective

  2007cited by this paper
• Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire

  2005cited by this paper
• World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.

  2000cited by this paper
• Psychometric validation of a constipation symptom assessment questionnaire.

  1999cited by this paper
• Stool form scale as a useful guide to intestinal transit time.

  1997cited by this paper

• 만성변비의 진단과 치료에 관한 서울 진료지침

  2025cites this paper
• Clinical effects of chemical drugs, fecal microbiota transplantation, probiotics, dietary fiber, and acupuncture in the treatment of chronic functional constipation: a systematic review and network meta-analysis

  2024cites this paper
• Engineering of Novel Analogues That Are More Receptor-Selective and Potent than the Native Hormone, Insulin-like Peptide 5 (INSL5).

  2024cites this paper
• Developing insulin-like peptide 5-based antagonists for the G protein-coupled receptor, RXFP4.

  2024cites this paper
• Prokinetics‐safety and efficacy: The European Society of Neurogastroenterology and Motility/The American Neurogastroenterology and Motility Society expert review

  2024influential citation
• Clinical Outcomes Before and After Prucalopride Treatment: An Observational Study in Patients With Chronic Idiopathic Constipation in the United States

  2024cites this paper
• Patient reported outcomes in Disorders of Gut-Brain Interaction.

  2024cites this paper
• Efficacy and safety of prucalopride in patients with chronic idiopathic constipation stratified by age, body mass index, and renal function: a post hoc analysis of phase III and IV, randomized, placebo-controlled clinical studies

  2024cites this paper
• Chronic constipation: from pathophysiology to management.

  2023cites this paper
• 2022 Seoul Consensus on Clinical Practice Guidelines for Functional Constipation

  2023cites this paper
• Gut indigenous Ruminococcus gnavus alleviates constipation and stress-related behaviors in mice with loperamide-induced constipation.

  2023cites this paper
• A Review of the Cardiovascular Safety of Prucalopride in Patients With Chronic Idiopathic Constipation

  2023cites this paper
• Tissue distribution and abuse potential of prucalopride: findings from non-clinical and clinical studies

  2023cites this paper
• Polyethylene Glycol 3350 in the Treatment of Chronic Idiopathic Constipation: Post hoc Analysis Using FDA Endpoints

  2022cites this paper
• Cannabis sativa L. alleviates loperamide-induced constipation by modulating the composition of gut microbiota in mice

  2022cites this paper
• Aktualisierte S2k-Leitlinie chronische Obstipation der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastroenterologie & Motilität (DGNM) – April 2022 – AWMF-Registriernummer: 021–019

  2022cites this paper
• Prokinetic Agents

  2022influential citation
• Role of Prucalopride in Treating Functional Constipation and Gastroparesis: A Systemic Review

  2021cites this paper
• Efficacy of Prucalopride for Chronic Idiopathic Constipation: An Analysis of Participants With Moderate to Very Severe Abdominal Bloating

  2021cites this paper
• Managing functional constipation: the course doesn’t always run smooth

  2021cites this paper
• Different doses of prucalopride in treating chronic idiopathic constipation: a meta-analysis and Bayesian analysis

  2021cites this paper
• Effects and sites of action of a M1 receptor positive allosteric modulator on colonic motility in rats and dogs compared with 5‐HT4 agonism and cholinesterase inhibition

  2020cites this paper
• Mechanisms, Evaluation, and Management of Chronic Constipation.

  2020cites this paper
• Comparative Efficacy of Drugs for the Treatment of Chronic Constipation

  2020cites this paper
• Impact of Clinical Outcome Measures on Placebo Response Rates in Clinical Trials for Chronic Constipation: A Systematic Review and Meta-analysis

  2020cites this paper
• Functional Constipation: Individualising Assessment and Treatment

  2020cites this paper
• Placebo response rate in patients with chronic constipation

  2020cites this paper
• Effect of different body position on anorectal manometry for chronic constipation patients.

  2019cites this paper
• Use of prucalopride in adults with chronic idiopathic constipation

  2019cites this paper
• Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis.

  2019cites this paper
• An overview of the efficacy and safety of prucalopride for the treatment of chronic idiopathic constipation

  2019cites this paper
• Placebo Response in Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis.

  2019cites this paper
• Recent advances in understanding and managing chronic constipation

  2018cites this paper
• Pharmacological Treatment of Opioid-Induced Constipation Is Effective but Choice of Endpoints Affects the Therapeutic Gain

  2018cites this paper
• 4-Substituted and 1,4-Disubstituted Piperidines

  2018cites this paper
• The Mexican consensus on chronic constipation

  2018cites this paper
• The Role of Bowel Management in Children with Bladder and Bowel Dysfunction

  2018cites this paper
• Comparison of acupuncture and other drugs for chronic constipation: A network meta-analysis

  2018cites this paper
• The Mexican consensus on chronic constipation.

  2018cites this paper
• Irritable Bowel Syndrome: Clinical Manifestations, Dietary Influences, and Management

  2017cites this paper
• The PAC‐SYM questionnaire for chronic constipation: defining the minimal important difference

  2017cites this paper
• Prokinetics in the Management of Functional Gastrointestinal Disorders

  2017cites this paper
• An update on prucalopride in the treatment of chronic constipation

  2017cites this paper
• Long-term outcome of sacral neuromodulation for chronic refractory constipation

  2017cites this paper
• New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond

  2017cites this paper
• Comparison of efficacy of pharmacological treatments for chronic idiopathic constipation: a systematic review and network meta-analysis

  2016cites this paper
• Prucalopride succinate for the treatment of constipation: an update

  2016cites this paper
• Disorders of gastrointestinal hypomotility

  2016cites this paper
• Patient considerations in the management of chronic constipation: focus on prucalopride

  2016cites this paper
• Sacral Nerve Stimulation Fails to Offer Long-term Benefit in Patients With Slow-Transit Constipation

  2016cites this paper
• Efficacy and Safety of Prucalopride in Chronic Constipation: An Integrated Analysis of Six Randomized, Controlled Clinical Trials

  2016cites this paper
• Patient considerations in the management of chronic constipation: focus on prucalopride

  2016cites this paper
• Childhood constipation: finally something is moving!

  2016cites this paper
• The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinson’s disease

  2015cites this paper
• Gastroparesia y otros síntomas gastrointestinales en la enfermedad de Parkinson

  2015cites this paper
• Prucalopride: A Review in Chronic Idiopathic Constipation

  2015influential citation
• Sa1390 Efficacy and Safety of Prucalopride in Chronic Constipation: An Integrated Analysis of Six Randomized Controlled Clinical Trials

  2015cites this paper
• [Gastroparesis and other gastrointestinal symptoms in Parkinson's disease].

  2015cites this paper
• New and Investigational Agents for Irritable Bowel Syndrome

  2015cites this paper